ASLAN Pharmaceuticals Announces Positive Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
San Mateo, Calif. and Singapore March 06, 2024 ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage biopharmaceutical company focused on immunology, has unveiled new promising translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of chronic obstructive pulmonary disease (COPD). This data further reinforces the potential of eblasakimab as a biologic therapy for COPD. Additionally, ASLAN Pharmaceuticals has appointed renowned respiratory experts, Dr. Ramaswamy Krishnan and Dr. Reynold Panettieri Jr. to its Scientific Advisory Board as it explores the potential use of eblasakimab to treat COPD and atopic dermatitis (AD).
COPD is a progressive lung disease characterized by persistent respiratory symptoms and airflow limitation. It affects millions of individuals worldwide and is a leading cause of morbidity and mortality. While current treatments aim to alleviate symptoms and reduce exacerbations, a disease-modifying therapeutic approach that can halt or reverse the progression of COPD remains a significant unmet need.
ASLAN’s eblasakimab is a novel biologic therapy that targets the interleukin-13 (IL-13) pathway, which has been implicated in the development and progression of COPD and AD. The recent head-to-head study compared eblasakimab with dupilumab, a biologic therapy approved for the treatment of certain allergic conditions. Results from the study demonstrated that eblasakimab had a superior effect in attenuating the inflammatory response in the human tissue model of COPD. This suggests that eblasakimab may have the potential to modulate the underlying disease processes of COPD and provide meaningful clinical benefits for patients.
In light of these encouraging findings, ASLAN Pharmaceuticals has welcomed two esteemed respiratory experts to its Scientific Advisory Board. Dr. Ramaswamy Krishnan, an Associate Professor in Emergency Medicine at Harvard Medical School, brings his extensive expertise in pulmonary and critical care medicine, while Dr. Reynold Panettieri Jr. Vice Chancellor for Translational Medicine and Science at Rutgers University, is renowned for his research in airway biology and mechanisms of asthma and COPD. Their valuable insights and guidance will aid ASLAN in its evaluation of eblasakimab as a potential therapy for both COPD and AD.
Dr. Mark McHale, Chief Medical Officer of ASLAN Pharmaceuticals, expressed his excitement for the new translational data and appointments, stating, This positive translational data confirms the potential of eblasakimab as a game-changing therapy for COPD. We are delighted to have Dr. Krishnan and Dr. Panettieri join our Scientific Advisory Board, bringing their immense knowledge and experience to help us further explore the therapeutic benefits of eblasakimab in COPD and AD.
The appointment of these esteemed experts not only underlines ASLAN Pharmaceuticals’ commitment to advancing innovative treatments for respiratory diseases but also highlights the growing recognition of eblasakimab as a promising therapy for COPD and other related conditions.
In conclusion, the newly released translational data showcases the potential of eblasakimab as a significant breakthrough in the treatment of COPD. ASLAN Pharmaceuticals’ decision to include Dr. Krishnan and Dr. Panettieri as scientific advisors further demonstrates their dedication to advancing the understanding and treatment of respiratory diseases. With this positive momentum, ASLAN Pharmaceuticals is set to drive innovation and transform the lives of patients suffering from COPD and other related conditions.
Comments